Aquestive Therapeutics, Inc. Stock News

Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Kristen Kluska - Cantor Fitzgerald Jason Butler - JMP Securities Rag...

WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a progress upd...

WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine subli...

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrine gel for alopecia areata, shows promise with minimal side effects and could expedite its regulatory path, targeting a billion-dollar market. Libervant, a diazepam buccal film for cluster seizures,...

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in a specialized B2B marketplace shows high-growth potential to Bert Hochfeld, making it a promising investment. Grassroots Trading argues that Boston Scientific's acquisition of Axonics enhances its ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Steve Wargacki - CSO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Francois Brisebois - Op...

Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price.